Anti-ADGRE5 / Adhesion G protein-coupled receptor E5 / CD97

Adding 0.2 ml of distilled water will yield a concentration of 500 ug/ml. ADGRE5 antibody detects Adhesion G protein-coupled receptor E5 (also known as CD97), a member of the E class of adhesion GPCRs that mediate cell-cell and cell-matrix interactions. Encoded by the ADGRE5 gene on chromosome 19p13.12, this receptor is composed of an extended extracellular region with multiple EGF-like repeats, a GPCR autoproteolysis-inducing (GAIN) domain, and a seven-transmembrane region typical of GPCRs. CD97 is expressed on leukocytes, smooth muscle cells, and epithelial cells, where it regulates adhesion, migration, and immune cell activation. The receptor interacts with multiple ligands, including CD55 (decay-accelerating factor), integrins, and chondroitin sulfate, which modulate immune responses and tissue remodeling.ADGRE5 undergoes autoproteolytic cleavage within the GAIN domain, producing a large extracellular alpha subunit and a smaller membrane-bound beta subunit that remain noncovalently associated. This processing is essential for receptor maturation and ligand binding. The EGF-like domains mediate interaction with CD55, linking ADGRE5 function to complement regulation and immune evasion. In immune cells, ADGRE5 participates in leukocyte migration to inflammatory sites, co-stimulation of T cells, and macrophage activation. It also contributes to angiogenesis, smooth muscle contraction, and cell-cell adhesion in epithelial tissues. Dysregulated expression of CD97 has been associated with inflammatory disorders and several cancers, where it promotes invasion, epithelial-mesenchymal transition, and metastasis.The ADGRE5 antibody is widely used in immunology, cancer biology, and vascular research to detect receptor expression and distribution. Western blot analysis identifies multiple bands (75-120 kilodaltons) corresponding to the various glycosylated receptor forms, while flow cytometry and immunohistochemistry reveal strong membrane localization. In tumors, overexpression of ADGRE5 enhances motility through interactions with integrins and activation of RhoA and MAPK pathways. Elevated expression correlates with poor prognosis in colorectal, thyroid, and gastric cancers. Conversely, in leukocytes, ADGRE5 expression is dynamically regulated during activation and differentiation, serving as a marker for immune cell subsets.Beyond cancer and inflammation, ADGRE5 participates in vascular remodeling and smooth muscle physiology. It mediates heterotypic interactions between leukocytes and endothelial cells, facilitating transmigration across the vessel wall. Experimental deletion of ADGRE5 in mice reduces inflammatory cell recruitment and limits tissue damage, underscoring its role in immune regulation. The ADGRE5 antibody enables detailed characterization of receptor expression and function across tissues and disease contexts. NSJ Bioreagents provides this antibody validated for its applications, ensuring specificity for both membrane-bound and cleaved receptor forms in human and model systems.